258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC).

Authors :: Muiño, C. Bueno
Diaz-Guardamino, I. Echavarria
Alvarez, E.
Gilarranz, Y. Jerez
Lopez, B. Herrero
Del Monte, M.
Massarrah, T.
Cebollero, M.
Nevado, M.
Barrio, P.D.L.M. de la Morena
Ayala de la Pena, F.
Saenz, J.Á. García
Anton, F. Moreno
Rodriguez, A.
Verduguez, T. Quintanar
Gimenez, D. Malon
Garcia, A.I. Ballesteros
Bañón, D.
Lopez-Tarruella Cobo, S.
Jimenez, M. Martin
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS323-S323. 1p.
Publication Year :: 2024

Full Text Access

Tools